Last update June 26, 2022
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
7-{4-[4-(1-Benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one is Brexpiprazole in Chemical name.
Is written in other languages:7-{4-[4-(1-Benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one belongs to these groups or families:
Main tradenames from several countries containing 7-{4-[4-(1-Benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 95 | % |
Molecular weight | 434 | daltons |
Protein Binding | > 99 | % |
VD | 1.56 | l/Kg |
pKa | 13.56 | - |
Tmax | 4 | hours |
T½ | 91 - 96 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by IHAN of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is an atypical or second generation antipsychotic indicated in the treatment of schizophrenia and major depressive disorder. Oral administration once daily.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data (very high percentage of protein binding, moderately high molecular weight and very wide volume of distribution) make it highly unlikely that significant quantities will pass into breast milk.
Brexpiprazole produces a minimal increase in prolactin levels. (Clayton 2020, Ivkovic 2019, Ishigooka 2018)
A doubtful cause of lactation suppression attributed to brexpiprazole has been published. (Berlin 2020)
Until there is further published data on this drug in relation to breastfeeding, known safer alternatives are preferable (Wichniak 2021), especially during the neonatal period and in cases of prematurity.
See below the information of these related products: